Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms

Abstract Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the landscape of DLL3 at the mRNA and protein levels ac...

Full description

Saved in:
Bibliographic Details
Main Authors: Alejandra G. Serrano, Pedro Rocha, Cibelle Freitas Lima, Allison Stewart, Bingnan Zhang, Lixia Diao, Junya Fujimoto, Robert J. Cardnell, Wei Lu, Khaja Khan, Beate Sable, Aaron R. Ellison, Ignacio I. Wistuba, Kyle F. Concannon, Daniel M. Halperin, Czerniak Bogdan, Kanishka Sircar, Miao Zhang, Kasey Cargill, Qi Wang, Ana Aparicio, Alexander Lazar, Sharia Hernandez, Jeannelyn Estrella, Preetha Ramalingam, Adel El-Naggar, Neda Kalhor, Carl M. Gay, Lauren Averett Byers, Luisa M. Solis Soto
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00739-y
Tags: Add Tag
No Tags, Be the first to tag this record!